Table of Contents
Volume 8 | Issue 2
Publication Date: April 2008- Abstract
- No Access
- Pay-Per View
- Full Text
- Add to Cart
Editorial | ||
111 |
Pill-Popping and Therapeutic Outcome George W. Sledge, Jr |
|
Comprehensive Reviews | ||
124-133 |
Low-Dose Estrogen Therapy to Reverse Acquired Antihormonal Resistance in the Treatment of Breast Cancer Ramona F. Swaby, V. Craig Jordan |
|
134-142 |
Defining the Role for Autologous Breast Reconstruction After Mastectomy: Social and Oncologic Implications Warren Matthew Rozen, Mark W. Ashton, G. Ian Taylor |
|
Original Contributions | ||
143-148 |
Method of Primary Tumor Detection as a Risk Factor for Local and Distant Recurrence After Breast-Conservation Treatment for Early-Stage Breast Cancer Julia Tchou, Joel Greshock, Meredith R. Bergey, Seema S. Sonnad, Michael Sargen, Susan Weinstein, Brian J. Czerniecki, Marcia Boraas, Douglas L. Fraker, Ernest Rosato, Kevin Fox, Barbara Weber, Lawrence J. Solin |
|
149-154 |
A Phase II Study of Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes Laura G. Estévez, Norberto Batista, Pedro Sánchez-Rovira, Amalia Velasco, Mariano Provencio, Ana León, Manuel Dómine, Josefina Cruz, Milva Rodríguez |
|
155-161 |
Insight into Barriers Against Optimal Adherence to Oral Hormonal Therapy in Women with Breast Cancer Margaret C. Kirk, Clifford A. Hudis |
|
162-167 |
A Phase II Trial of Split, Low-Dose Docetaxel and Low-Dose Capecitabine: A Tolerable and Efficacious Regimen in the First-Line Treatment of Patients with HER2/neu–Negative Metastatic Breast Cancer Orlando Silva, Gilberto Lopes, Daniel Morgenzstern, Christopher Lobo, Philomena Doliny, Edgardo Santos, Sakher Abdullah, Umang Gautam, Isildinha Reis, Catherine Welsh, Joyce Slingerland, Judith Hurley, Stefan Gluck |
|
168-177 |
Plasminogen Activator Inhibitor Type 1 is the Most Significant of the Usual Tissue Prognostic Factors in Node-Negative Breast Ductal Adenocarcinoma Independent of Urokinase-Type Plasminogen Activator Françoise Descotes, Benjamin Riche, Simone Saez, Guy De Laroche, Jean Datchary, Pascal Roy, Jean André, Jean Yves Bobin |
|
178-186 |
Phase II Trial of Gemcitabine/Carboplatin (plus Trastuzumab in HER2-Positive Disease) in Patients with Metastatic Breast Cancer David Loesch, Lina Asmar, Kristi McIntyre, Lisa Doane, Michael Monticelli, Devchand Paul, Svetislava Vukelja, Mauro Orlando, LaTrice G. Vaughn, Feng Zhan, Kristi A. Boehm, Joyce A. O'Shaughnessy |
|
Case Reports | ||
187-188 |
Primary Mucosa-Associated Lymphoid Tissue Lymphoma of the Breast Ramji R. Rajendran, Juan P. Palazzo, Gordon F. Schwartz, John H. Glick, Lawrence J. Solin |
|
189-191 |
Primary Carcinoma of Ectopic Breast Tissue Fabio Corsi, Alessandra Sartani, Andrea Rizzi, Maria Antonietta Nosenzo, Diego Foschi, Silvia Alineri, Emili Trabucchi |
|
Current Trial | ||
192-194 |
Preoperative Chemotherapy plus Lapatinib or Trastuzumab or Both in HER2-Positive Operable Breast Cancer (CHERLOB Trial) Valentina Guarneri, Antonio Frassoldati, Federico Piacentini, Gordana Jovic, Simona Giovannelli, Cristina Oliva, PierFranco Conte |
|
Clinical Trials | ||
195 |
Selected Clinical Trials in Breast Cancer CIG Media Group |
|